Non-dilutive working capital for Bay Area operators.

Tech company cash flow in the Bay Area follows patterns that traditional lenders frequently misunderstand. A SaaS company with $15M ARR and 120% net revenue retention may still run cash-negative for 18+ months while investing in sales capacity ahead of recognized revenue. These companies don't fit bank underwriting models built around historical profitability — yet their forward economics are strong and their capital needs are immediate: engineering talent commands $200-400K fully loaded, commercial office space in San Francisco runs $70-85 per square foot annually, and sales teams require 6-9 month ramp periods before generating attributable revenue. Non-dilutive facilities that underwrite against contracted ARR or recurring revenue velocity fill a critical gap between venture rounds.

The startup-to-growth transition — companies moving from Series A/B into sustained scaling — creates a distinct capital need that neither venture equity nor traditional debt serves well. Companies at $5-20M in revenue with strong unit economics often face a choice: raise another equity round at 20-30% dilution, or find non-dilutive capital that bridges to profitability or a more favorable valuation for the next raise. Revenue-based financing, recurring revenue credit lines, and contract-backed facilities serve this exact moment — providing $1-10M in growth capital without cap table impact during the 12-24 months where dilution is most expensive.

Bay Area commercial real estate costs create a unique overhead burden that compounds working capital needs. A 10,000-square-foot office in SoMa or South of Market costs $700K-$850K annually in rent alone — before buildout, furniture, and operating expenses. Biotech lab space in South San Francisco commands $80-100 per square foot triple-net. Companies navigating lease commitments, expansion into additional space, or sublease transitions during headcount changes face capital gaps that are purely real-estate-driven. Meanwhile, biotech R&D funding gaps between clinical milestones (typically 12-24 months between Phase I and Phase II data readouts) require bridge capital to maintain operations, retain scientific staff, and continue preclinical work while awaiting results that will unlock the next institutional investment.